In the present study, a patient selection algorithm was applied in an established BC registry for patients with advanced BC, using the inclusion and exclusion criteria of a phase 2 study (SHERBOC) with the anti-HER3 antibody seribantumab (NCT03241810 and 2017–000565-76). This evidence concerns the gene ERBB3 and breast cancer.